Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 2/20 | 0.31 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23179021 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ESR1ESR2KRASKIF11 | |
| SCHEMBL24702322 | 0.91 | ESR1 (0.35) | ALDH1A1ESR1ESR2KCNQ3KCNQ2 | |
| SCHEMBL26786958 | 0.87 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL23206538 | 0.83 | ESR1 (0.34) | ESR1ESR2KRASKIF11KCNQ3 | |
| SCHEMBL25540046 | 0.83 | ESR1 (0.34) | ESR1ESR2KRASKIF11KCNQ3 | |
| SCHEMBL25956536 | 0.83 | ESR1 (0.34) | ESR1ESR2KRASKIF11KCNQ3 | |
| SCHEMBL23158213 | 0.80 | ESR1 (0.34) | ESR1ESR2KRASKIF11TLR7 | |
| SCHEMBL18500158 | 0.80 | KIF11 (0.32) | KIF11KCNQ3KCNQ2 | |
| SCHEMBL15697026 | 0.80 | KIF11 (0.32) | KIF11KCNQ3KCNQ2 | |
| SCHEMBL13600547 | 0.80 | KIF11 (0.32) | KIF11KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | ALDH1A1 3174/4885ESR1 3421/4885ESR2 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.